COMBINATION OF AN EGFR T790M INHIBITOR AND A CDK INHIBITOR FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER - Patent 3541389

(19)

(11)

EP 3 541 389 A1

(12)

(43)	Date of publication:
	25.09.2019 Bulletin 2019/39

(21)	Application number: 17808168.3

(22)	Date of filing: 07.11.2017

(51)

International Patent Classification (IPC):

A61K 31/519^(2006.01)
A61P 35/00^(2006.01)

A61K 31/52^(2006.01)

(86)	International application number:
	PCT/IB2017/056952

(87)	International publication number:
	WO 2018/091999 (24.05.2018 Gazette 2018/21)

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME
	Designated Validation States:
	MA MD

(30)

Priority:

16.11.2016 US 201662423146 P
11.10.2017 US 201762571114 P

(71)	Applicant: Pfizer Inc.
	New York, NY 10017 (US)

(72)	Inventors:
	GOLDBERG, Zelanna Iris San Diego, California 92122 (US) WANG, Yuli San Diego, California 92130 (US) WEINRICH, Scott Lawrence San Diego, California 92130 (US) WILNER, Keith David La Jolla, California 92037 (US)

(74)	Representative: Pfizer
	European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 75668 Paris Cedex 14 (FR)

(54)	COMBINATION OF AN EGFR T790M INHIBITOR AND A CDK INHIBITOR FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER